Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Century Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing induced pluripotent stem cell (iPSC)–derived cell therapies for cancer. The company operates within the biotechnology and cell therapy industries, with a core emphasis on off-the-shelf allogeneic immune cell products designed to overcome limitations of patient-specific autologous therapies. Its programs primarily target hematologic malignancies and solid tumors using engineered natural killer (NK) cells and T cells.
Century Therapeutics was founded in 2018 and went public in 2021. The company was established to commercialize advances in iPSC biology, gene editing, and immuno-oncology, positioning itself as a next-generation cell therapy platform company. Its strategy centers on scalable manufacturing, repeat dosing potential, and consistent product quality, which management believes may provide advantages over autologous CAR-T approaches.
Business Operations
The company’s operations are organized around two primary therapeutic platforms: iPSC-derived NK cell therapies and iPSC-derived T cell therapies. Revenue generation to date has been limited and primarily related to collaboration and research agreements, as the company remains in the clinical development stage and does not yet have approved commercial products.
Century Therapeutics controls proprietary iPSC differentiation and genetic engineering technologies that enable the production of uniform immune cell populations. The company has entered into strategic collaborations, including a significant partnership with Bristol Myers Squibb to research and develop iPSC-derived NK cell therapies, and a manufacturing relationship with FUJIFILM Cellular Dynamics, Inc., a leading iPSC manufacturing organization. These partnerships support development, scale-up, and clinical supply capabilities.
Strategic Position & Investments
Strategically, Century Therapeutics is focused on advancing its wholly owned clinical pipeline while leveraging partnerships to offset development risk and capital intensity. Key growth initiatives include progressing lead programs in hematologic malignancies and expanding into solid tumor indications using enhanced cell persistence and tumor-targeting technologies.
The company has invested heavily in gene-editing capabilities, including multiplex editing to improve potency, persistence, and immune evasion. While Century does not operate a broad investment portfolio, it maintains exclusive or licensed rights to foundational iPSC intellectual property and continues to evaluate in-licensing and acquisition opportunities that complement its cell therapy platforms. Its collaboration with Bristol Myers Squibb represents a notable external validation of its technology.
Geographic Footprint
Century Therapeutics is headquartered in the United States, with principal operations in Pennsylvania and California. Its research, development, and corporate functions are primarily U.S.-based, reflecting the country’s concentration of biotechnology talent and regulatory infrastructure.
Internationally, the company’s footprint is indirect, achieved through global partnerships and clinical trial planning rather than owned facilities. Its collaboration with Bristol Myers Squibb, a multinational biopharmaceutical company, and its engagement with global manufacturing partners provide Century with international reach and potential future access to non-U.S. markets.
Leadership & Governance
Century Therapeutics is led by an executive team with prior experience in cell therapy development, large biopharmaceutical organizations, and clinical translation. The leadership emphasizes disciplined clinical execution, scalable manufacturing, and long-term platform value creation as central elements of its strategic vision.
Key executives include:
- Brent E. Pfeiffenberger – President and Chief Executive Officer
- Daniel J. Chen – Chief Financial Officer
- Kenneth W. Lee, MD – Chief Scientific Officer
- Anthony J. Paolillo – Chief Legal and Administrative Officer
The company is governed by a board of directors comprising biotechnology executives, investors, and scientific leaders, consistent with governance practices of publicly traded U.S. biotechnology companies.